newswire, breaking biotechnology and pharma news

Thursday, June 21, 2012

Biopharmaceutical Stock Alert: Onyx Pharmaceuticals (NASDAQ: ONXX) Big Moves on FDA Positive Vote

New York, New York - June 21, 2012 ( Newswire), an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), one of the NASDAQ’s top gainers, trading at $62.18, up $17.60 or (39.48%) as of 11:14AM EDT on over 16 Million shares. The stock has a morning high of $63.22.
The Company announced yesterday that the U.S. FDA's Oncologic Drugs Advisory Committee (ODAC) determined by a vote of 11-0 [with 1 abstention] that, in patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent (IMiD), the benefit-risk assessment is favorable for the use of Kyprolis� (proposed brand name for carfilzomib). Onyx is developing Kyprolis for use in multiple myeloma across a variety of treatment lines. Newswire About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at

About is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow on Twitter!/ Investorideas
Follow on Facebook Investorideas
Sign up for the free investor news and stock alerts at
Research biotech stocks at the Biotech stocks Directory and biotech news and research at
Become an Member membership/
Follow on Twitter!/Investorideas
Follow on Facebook
Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
Source -

No comments:

Post a Comment